Company news

Corvus Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

November 8, 2024

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

September 9, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

August 5, 2024

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

July 31, 2024

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 5, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

May 1, 2024

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

April 8, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 18, 2024

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

February 11, 2024

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

February 7, 2024

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

February 5, 2024

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

January 22, 2024

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

December 8, 2023

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

November 6, 2023

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

October 31, 2023

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

September 5, 2023

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

August 7, 2023

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

July 31, 2023

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

July 5, 2023

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

June 28, 2023

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

May 7, 2023

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

April 19, 2023

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

April 16, 2023

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 27, 2023

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

February 20, 2023

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

December 4, 2022

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

November 2, 2022

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

October 24, 2022

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

September 25, 2022

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

August 7, 2022

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

July 20, 2022

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

May 4, 2022

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

April 25, 2022

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 9, 2022

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

March 2, 2022

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

January 12, 2022

Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 11, 2021

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

October 31, 2021

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

October 26, 2021

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

September 21, 2021

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

September 6, 2021

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

August 15, 2021

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

August 1, 2021

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

July 14, 2021

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

May 4, 2021

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

April 28, 2021

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

March 24, 2021

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

February 16, 2021

Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

February 11, 2021

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

February 10, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.